Chemicals
In Q2 FY2026, Sherwin-Williams delivered 7.5% revenue growth to $6.789B and 14.3% diluted EPS growth to $3.43, supported by higher sales across all segments and the Suvinil acquisition, although raw-material inflation, higher interest costs, and weaker working-capital metrics remained notable constraints. Source: 10-Q Item 2 MD&A, pp.27-34
Key risk: Near-term liquidity and working-capital pressure
Current assets of $6.999B were below current liabilities of $9.627B, producing a current ratio of 0.73 and a working-capital deficit of $2.628B at June 30, 2026. Current liabilities increased faster than current assets, driven in part by higher short-term borrowings and the current portion of long-term debt; this can increase reliance on operating cash flow and borrowing capacity.
Other Specialty Chemicals companies